Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Accounts Payables (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Accounts Payables for 6 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 46.09% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 46.09% year-over-year, with the annual reading at $2.9 million for FY2025, 46.09% down from the prior year.
  • Accounts Payables hit $2.9 million in Q4 2025 for Lyell Immunopharma, up from $2.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.5 million in Q1 2022 to a low of $2.6 million in Q3 2025.
  • Historically, Accounts Payables has averaged $4.3 million across 5 years, with a median of $4.2 million in 2022.
  • Biggest five-year swings in Accounts Payables: plummeted 65.87% in 2021 and later soared 36.68% in 2023.
  • Year by year, Accounts Payables stood at $3.2 million in 2021, then grew by 22.14% to $3.9 million in 2022, then rose by 22.98% to $4.8 million in 2023, then grew by 11.4% to $5.4 million in 2024, then crashed by 46.09% to $2.9 million in 2025.
  • Business Quant data shows Accounts Payables for LYEL at $2.9 million in Q4 2025, $2.6 million in Q3 2025, and $3.4 million in Q2 2025.